Overview

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.
Phase:
Phase 3
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Paroxetine